| Open Trial |
Description |
|
NCIC CTG
OV-16
|
A phase III study of Cisplatin plus Topotecan followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as first line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer. Contact: Fern Lowe |
| Schering Canada Inc. (PO3625) |
Phase II Open-label Study of Caelyx and Carboplatin in Platinum-Sensitive Relapsed Epithelial Ovarian Cancer
Contact: Fern Lowe |
|
Dr. Mirchandani
(In-house) |
Phase II Study of Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers
Contact: Fern Lowe |
